Details for Patent: 8,746,242
✉ Email this page to a colleague
Which drugs does patent 8,746,242 protect, and when does it expire?
Patent 8,746,242 protects INCRUSE ELLIPTA, ANORO ELLIPTA, ARNUITY ELLIPTA, BREO ELLIPTA, and TRELEGY ELLIPTA, and is included in five NDAs.
Protection for ANORO ELLIPTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has twenty-seven patent family members in twenty countries.
Summary for Patent: 8,746,242
| Title: | Medicament dispenser |
| Abstract: | A medicament dispenser for use with at least one medicament carrier carrying multiple distinct medicament portions, said medicament dispenser comprising (a) a dispensing mechanism actuable for dispensing the distinct medicament portions carried by the at least one medicament carrier; (b) a mouthpiece; and (c) a cover for the mouthpiece, the cover being movably mounted to the dispenser for sequential movement from a first position, in which the mouthpiece is covered, to a second position, in which the mouthpiece is at least part-uncovered, to a third position in which the mouthpiece is uncovered; wherein the cover is adapted to couple with the dispensing mechanism such that movement of the cover from the second position to the third position, but not the first position to the second position, results in actuation of the dispensing mechanism. |
| Inventor(s): | Connell; Hugh Alexander (Evesham, GB), Harvey; Stephen James (Ware, GB), Tansley; Robert William (Bidford on Avon, GB) |
| Assignee: | Glaxo Group Limited (Brentford, Middlesex, GB) |
| Application Number: | 11/996,762 |
|
Patent Claim Types: see list of patent claims | Composition; Device; Use; |
Drugs Protected by US Patent 8,746,242
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxo Grp England | INCRUSE ELLIPTA | umeclidinium bromide | POWDER;INHALATION | 205382-001 | Apr 30, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Glaxosmithkline | ANORO ELLIPTA | umeclidinium bromide; vilanterol trifenatate | POWDER;INHALATION | 203975-001 | Dec 18, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Glaxosmithkline | ARNUITY ELLIPTA | fluticasone furoate | POWDER;INHALATION | 205625-003 | May 17, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Glaxosmithkline | ARNUITY ELLIPTA | fluticasone furoate | POWDER;INHALATION | 205625-001 | Aug 20, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Glaxosmithkline | ARNUITY ELLIPTA | fluticasone furoate | POWDER;INHALATION | 205625-002 | Aug 20, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,746,242
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0515584.1 | Jul 28, 2005 |
| PCT Information | |||
| PCT Filed | July 27, 2006 | PCT Application Number: | PCT/GB2006/002831 |
| PCT Publication Date: | February 01, 2007 | PCT Publication Number: | WO2007/012871 |
International Family Members for US Patent 8,746,242
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2006273856 | ⤷ Sign Up | |||
| Brazil | PI0614568 | ⤷ Sign Up | |||
| Canada | 2616193 | ⤷ Sign Up | |||
| China | 101272818 | ⤷ Sign Up | |||
| Cyprus | 1122241 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
